Eli Lilly (NYSE:LLY) reported Phase 3 results for obesity drugs retatrutide and Foundayo at the American Diabetes Association 86th Scientific Sessions in 2026. The data show strong weight loss ...
A 12-year-old walking into a pediatrician’s office today can walk out with a prescription for the same class of drug that has reshaped adult weight loss culture, emptied gym memberships in favor of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results